MRTX - FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer | Benzinga
FDA advisers concluded that the data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's (NASDAQ: AMGN) Lumakras for patients afflicted with an advanced form of lung cancer.
During the meeting, the FDA's expert advisers voted 10 'no' to 2 'yes', expressing doubts about relying on the primary goal ...